Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis

NCT05461131 is registered in ClinicalTrials.gov with ILiAD Biotechnologies as lead sponsor.

NCT NCT05461131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy Adults to Assess Protection Against Colonization Following Challenge With Virulent Wild-Type Bordetella Pertussis
Lead sponsor
ILiAD Biotechnologies
Phase
Phase 2
Overall status
Completed
Start date
June 20, 2022
Completion date
October 26, 2023
Enrollment
53 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bordetella pertussis, whooping cough, pertussis/whooping cough